I challenged a mistaken fall risk label before my transplant and proved that self-advocacy is crucial to both quality care and emotional well-being.
Even after surgery and chemotherapy, I make sure to shine through cancer and any fear that stares at me.
The Cancer Support Community's Biomarker Testing Tool can help identify which targeted therapy should be used for treatment in patients with lung cancer.
The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and targeted therapies like Orserdu.
Living with follicular lymphoma, I’ve learned many assumptions about cancer, remission and treatment side effects don’t reflect the reality I face.
Breast cancer cracked me open but didn’t break me — it gave me voice, purpose and courage to dream boldly, live fully and speak up for those who can’t.
My wife, Michelle, has used this diagnosis as a pillar of strength, doing all she can for her young boys and me and leading the best life she can, while along the way committing to raise funds and awareness to help improve and extend the lives of patients with myeloma
Deborah Pickworth, who is living with stage 4 lung cancer, was nominated for the Lung Cancer Heroes® award for her impact in supporting and advocating for others with the disease.
Paula Schneider, president and CEO of Susan G. Komen®, writes to her younger self on the lessons and challenges she faced as a patient with breast cancer.
Even six years after brain tumor surgery, invisible symptoms like brain fog and memory loss shape how I live, cope, and find gratitude every day.
A patient with breast cancer details how her oncology nurse has helped her when experiencing side effects to the chemotherapy she’s receiving.
Dr. Ari Hakimi highlighted how tumor profiling and molecular markers are expanding access to precision-based trials for kidney cancer.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
I used to think that having lung cancer canceled all of my life's plans, but I realized I shouldn't give it that much power.
Livia Szeto, B.S.N., RN, OCN, has "unparalleled" patient relationships and research skills, allowing her to provide excellent care.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
On multiple occasions, doctors told me not to worry, but I ended up being diagnosed with a rare cancer called leiomyosarcoma.
Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.
How can colonoscopy detect colorectal cancer early and prevent it by removing polyps, compared with other noninvasive screening methods?
Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.
One morning after interdisciplinary team rounding, Mr. R asked Ashley to stay in his room. He had multiple questions about treatment options, and Ashley answered his questions in detail.
A cancer survivor writes about the oncologist who helped him conquer the fears and anxieties of cancer treatments.
New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.
Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.
IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.
Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.